Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Shares Acquired by Farallon Capital Management LLC

Farallon Capital Management LLC grew its holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 0.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,674,466 shares of the biopharmaceutical company's stock after purchasing an additional 13,600 shares during the quarter. Farallon Capital Management LLC owned about 9.95% of Agios Pharmaceuticals worth $186,463,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Summit Investment Advisors Inc. grew its holdings in shares of Agios Pharmaceuticals by 7.1% during the 4th quarter. Summit Investment Advisors Inc. now owns 5,913 shares of the biopharmaceutical company's stock worth $194,000 after purchasing an additional 394 shares during the period. Federated Hermes Inc. boosted its stake in Agios Pharmaceuticals by 4.4% during the fourth quarter. Federated Hermes Inc. now owns 13,691 shares of the biopharmaceutical company's stock worth $450,000 after buying an additional 582 shares during the period. KBC Group NV boosted its stake in Agios Pharmaceuticals by 30.5% during the fourth quarter. KBC Group NV now owns 2,615 shares of the biopharmaceutical company's stock worth $86,000 after buying an additional 611 shares during the period. Alliancebernstein L.P. boosted its stake in Agios Pharmaceuticals by 1.2% during the fourth quarter. Alliancebernstein L.P. now owns 61,500 shares of the biopharmaceutical company's stock worth $2,021,000 after buying an additional 708 shares during the period. Finally, Atria Investments Inc increased its holdings in Agios Pharmaceuticals by 6.9% in the 4th quarter. Atria Investments Inc now owns 11,365 shares of the biopharmaceutical company's stock valued at $373,000 after purchasing an additional 737 shares during the last quarter.

Analysts Set New Price Targets

A number of analysts recently issued reports on AGIO shares. StockNews.com raised Agios Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Saturday. HC Wainwright initiated coverage on Agios Pharmaceuticals in a report on Monday, February 24th. They issued a "buy" rating and a $58.00 price target for the company. Finally, Scotiabank dropped their price objective on Agios Pharmaceuticals from $74.00 to $71.00 and set a "sector outperform" rating on the stock in a report on Friday, May 2nd. Five analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $56.00.

Agios Pharmaceuticals Stock Down 2.8%

Shares of AGIO traded down $0.80 during trading hours on Wednesday, reaching $27.94. 246,845 shares of the company traded hands, compared to its average volume of 694,209. The stock has a market capitalization of $1.62 billion, a PE ratio of 2.46 and a beta of 0.77. Agios Pharmaceuticals, Inc. has a fifty-two week low of $23.42 and a fifty-two week high of $62.58. The stock has a fifty day simple moving average of $29.03 and a 200 day simple moving average of $37.00.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last released its earnings results on Thursday, May 1st. The biopharmaceutical company reported ($1.55) EPS for the quarter, beating the consensus estimate of ($1.80) by $0.25. The firm had revenue of $8.73 million during the quarter, compared to analyst estimates of $9.86 million. Agios Pharmaceuticals had a negative return on equity of 2.51% and a net margin of 1,845.92%. Research analysts predict that Agios Pharmaceuticals, Inc. will post -6.85 EPS for the current fiscal year.

Insider Activity at Agios Pharmaceuticals

In other news, Director Jacqualyn A. Fouse sold 7,497 shares of the firm's stock in a transaction dated Thursday, April 10th. The stock was sold at an average price of $25.90, for a total value of $194,172.30. Following the transaction, the director now directly owns 149,220 shares in the company, valued at $3,864,798. This trade represents a 4.78% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 4.30% of the company's stock.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.